Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shabana Shahid

Gastroenterology High Point, NC Medical Doctor

NPI 1871731836 CMS profile 130801

1580 Skeet Club Rd, High Point, NC 27265

Open in the dashboard

General payments

$20,568

570 records reported · program years 2019–2025

Research payments

$7,230

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$69,448 paid to institutions, not to them · program years 2021–2023

Through program year 2025, Shabana Shahid of High Point, NC is reported in the CMS Open Payments database as having received $20,568 across 570 general payments and $7,230 in research payments paid to them. Separately, studies naming them as principal investigator received $69,448 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,631 92
2024 General $13,310 127
2023 General $1,869 120
2022 General $1,800 111
2021 General $1,062 71
2020 General $305 17
2020 Research $7,230 1
2019 General $592 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shabana Shahid
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Shabana Shahid were reported at $1,631. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Shabana Shahid Gastroenterology median Middle half National median
2019 $592 $417 $126–$1,100 $163
2020 $305 $224 $74–$624 $114
2021 $1,062 $352 $106–$1,054 $132
2022 $1,800 $448 $129–$1,270 $149
2023 $1,869 $533 $150–$1,390 $160
2024 $13,310 $605 $160–$1,606 $164
2025 $1,631 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $11,884 38 payments
  2. AbbVie, Inc. $2,466 179 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $956 65 payments
  4. Janssen Biotech, Inc. $581 32 payments
  5. Celgene Corporation $487 32 payments
  6. Gilead Sciences, Inc. $432 18 payments
  7. Regeneron Healthcare Solutions, Inc. $351 14 payments
  8. Genzyme Corporation $316 17 payments
  9. Lilly USA, LLC $307 17 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $281 17 payments
  11. Other $2,508 141 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $9,800 1 payment
  2. Food and Beverage $9,742 560 payments
  3. Travel and Lodging $1,003 7 payments
  4. Education $23 2 payments
Products named General payments · program years 2019–2025
  1. INTERSTIM $11,884 38 payments
  2. MAVYRET $994 58 payments
  3. XIFAXAN $710 43 payments
  4. LINZESS $661 64 payments
  5. STELARA $572 31 payments
  6. RINVOQ $506 37 payments
  7. ZEPOSIA $503 33 payments
  8. CREON $348 29 payments
  9. DUPIXENT Immunology $299 16 payments
  10. DUPIXENT Inflammation And Immunology $274 11 payments
  11. Other $4,964 313 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $7,230 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,166

Median for Gastroenterology: 569

Drug cost

$396,414

Median for Gastroenterology: $104,976

Branded share of claims

40.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 24 $192,855
Linzess Linaclotide Brand 79 $74,135
Xifaxan Rifaximin Brand 12 $39,641
Trulance Plecanatide Brand 22 $23,331
Myrbetriq Mirabegron Brand 31 $16,362
Dexlansoprazole Dr Dexlansoprazole Brand 37 $12,324
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 181 $11,690
Sucralfate Generic 84 $8,159
Mesalamine Generic 17 $5,692
Omeprazole Generic 215 $3,571

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$27,266

Medicare's payments for the services billed

Medicare patients

121

Average age 69

Services billed

995

72 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 49%
Arthritis 40%
Depression 22%
Chronic kidney disease 21%
Ischemic heart disease 20%
COPD 17%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $163
  • GENZYME CORPORATION $67
$230 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $206
$206 — —
MAVYRET
  • AbbVie, Inc. $176
$176 — —
LINZESS
  • AbbVie, Inc. $113
  • Ironwood Pharmaceuticals, Inc $34
$147 79 —
STELARA
  • Janssen Biotech, Inc. $128
$128 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

571 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record